Aurinia Pharmaceuticals Company Profile (NASDAQ:AUPH)

About Aurinia Pharmaceuticals (AUPH)

Aurinia Pharmaceuticals logoAurinia Pharmaceuticals Inc. is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company's primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN. Voclosporin is an oral drug, administered twice daily. It is structurally similar to cyclosporine A (CsA), but is chemically modified on the amino acid-1 residue. It has completed two Phase III clinical studies in patients with moderate to severe psoriasis. It has completed Phase IIb clinical trial, which is a randomized, controlled, double-blind study comparing the efficacy of voclosporin as a component of multi-targeted therapy against placebo in achieving remission in patients with active LN.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: AUPH
  • CUSIP: N/A
Key Metrics:
  • Previous Close: $8.02
  • 50 Day Moving Average: $5.48
  • 200 Day Moving Average: $3.56
  • 52-Week Range: $53,428,000.00 - $1.74
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -17.43
  • P/E Growth: 0.00
  • Market Cap: $428.49M
  • Outstanding Shares: 53,428,000
  • Beta: 2.87
Profitability:
  • Net Margins: -9,512.50%
  • Return on Equity: -109.61%
  • Return on Assets: -66.44%
Debt:
  • Current Ratio: 3.64%
  • Quick Ratio: 3.64%

Analyst Ratings

Consensus Ratings for Aurinia Pharmaceuticals (NASDAQ:AUPH) (?)
Ratings Breakdown: 6 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $10.40 (29.68% upside)

Analysts' Ratings History for Aurinia Pharmaceuticals (NASDAQ:AUPH)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
3/22/2017FBR & CoReiterated RatingOutperform -> Outperform$9.00 -> $11.00LowView Rating Details
3/11/2017Canaccord GenuitySet Price TargetBuy$10.00HighView Rating Details
3/3/2017HC WainwrightBoost Price TargetPositive$8.00 -> $12.00N/AView Rating Details
3/2/2017Leerink SwannBoost Price TargetOutperform$7.00 -> $11.00N/AView Rating Details
11/4/2016Bloom BurtonReiterated RatingBuyN/AView Rating Details
11/2/2016MackieReiterated RatingBuy$8.00N/AView Rating Details
5/8/2015MLV & Co.Initiated CoverageBuy$9.00N/AView Rating Details
(Data available from 3/25/2015 forward)

Earnings

Earnings History for Aurinia Pharmaceuticals (NASDAQ:AUPH)
Earnings by Quarter for Aurinia Pharmaceuticals (NASDAQ:AUPH)
Earnings History by Quarter for Aurinia Pharmaceuticals (NASDAQ:AUPH)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/31/2015($0.11)($0.15)ViewN/AView Earnings Details
11/12/2014Q3 14($0.08)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Aurinia Pharmaceuticals (NASDAQ:AUPH)
Current Year EPS Consensus Estimate: $-0.26 EPS
Next Year EPS Consensus Estimate: $-0.46 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.14)($0.14)($0.14)
Q2 20161($0.15)($0.15)($0.15)
Q3 20162($0.15)($0.12)($0.14)
Q4 20162($0.10)($0.10)($0.10)
Q1 20172($0.13)($0.11)($0.12)
Q2 20171($0.11)($0.11)($0.11)
Q3 20171($0.12)($0.12)($0.12)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Aurinia Pharmaceuticals (NASDAQ:AUPH)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Aurinia Pharmaceuticals (NASDAQ:AUPH)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Headline Trends for Aurinia Pharmaceuticals (NASDAQ:AUPH)
Latest Headlines for Aurinia Pharmaceuticals (NASDAQ:AUPH)
Source:
DateHeadline
seekingalpha.com logoAurinia Pharmaceuticals: Fully Funded With Upcoming Catalysts
seekingalpha.com - March 24 at 4:07 PM
americanbankingnews.com logoQ1 2017 EPS Estimates for Aurinia Pharmaceuticals Inc Increased by FBR & Co (AUPH)
www.americanbankingnews.com - March 24 at 8:50 AM
finance.yahoo.com logoIs the Options Market Predicting a Spike in Aurinia Pharmaceuticals (AUPH) Stock?
finance.yahoo.com - March 22 at 4:15 PM
americanbankingnews.com logoFBR & Co Raises Aurinia Pharmaceuticals Inc (AUPH) Price Target to $11.00
www.americanbankingnews.com - March 22 at 9:52 AM
us.rd.yahoo.com logoAurinia Closes US$173.1 Million Public Offering of Common Shares and Full Exercise of Underwriters’ Option to Purchase Additional Common Shares
us.rd.yahoo.com - March 21 at 12:30 PM
americanbankingnews.com logoAurinia Pharmaceuticals Inc (AUPH) Upgraded to "Hold" by Zacks Investment Research
www.americanbankingnews.com - March 20 at 8:33 PM
feeds.benzinga.com logoDon't Let Offerings Blindside Your Thesis
feeds.benzinga.com - March 19 at 2:48 PM
nasdaq.com logoAurinia Prices Public Offering Of 22.30 Mln Common Shares At $6.75/Shr
www.nasdaq.com - March 16 at 5:14 PM
nasdaq.com logoAurinia Prices Public Offering Of 22.30 Mln Common Shares At $6.75/Shr
www.nasdaq.com - March 16 at 5:14 PM
rttnews.com logoAurinia Prices Offering At $6.75/Shr
www.rttnews.com - March 16 at 5:14 PM
rttnews.com logoAurinia Prices Offering At $6.75/Shr
www.rttnews.com - March 16 at 5:14 PM
capitalcube.com logoAurinia Pharmaceuticals, Inc. :AUPH-US: Earnings Analysis: 2016 By the Numbers : March 16, 2017
us.rd.yahoo.com - March 16 at 5:14 PM
us.rd.yahoo.com logoAurinia Announces Presentation at 12th International Congress on SLE (LUPUS 2017) & the 7th Asian Congress on Autoimmunity (ACA 2017)
us.rd.yahoo.com - March 16 at 5:14 PM
seekingalpha.com logoAurinia Pharmaceuticals: All Systems Go
seekingalpha.com - March 14 at 8:39 PM
marketwatch.com logoAurinia’s stock plunges after big share offering at deep discount
us.rd.yahoo.com - March 14 at 8:39 PM
americanbankingnews.com logoAurinia Pharmaceuticals Inc (AUPH) Earns “Outperform” Rating from FBR & Co
www.americanbankingnews.com - March 14 at 4:25 PM
businesswire.com logoAurinia Announces Public Offering of Common Shares
www.businesswire.com - March 14 at 3:39 PM
rttnews.com logoAurinia Pharmaceuticals Inc. (AUPH) Is Falling After Offering Announcement
www.rttnews.com - March 14 at 3:39 PM
marketwatch.com logoAurinia Pharmaceuticals shares drop on secondary offering plan
us.rd.yahoo.com - March 14 at 3:39 PM
us.rd.yahoo.com logoAurinia Prices US$150.5 Million Public Offering of Common Shares
us.rd.yahoo.com - March 14 at 3:39 PM
thestreet.com logoTwitter Traders Yap, but Aurinia Raising $150 Million was a Well-Executed Deal
us.rd.yahoo.com - March 14 at 3:39 PM
marketwatch.com logoAurinia’s stock plunges after large share offering at deep discount
www.marketwatch.com - March 14 at 3:39 PM
finance.yahoo.com logoAURINIA PHARMACEUTICALS INC. Financials
finance.yahoo.com - March 14 at 3:39 PM
americanbankingnews.com logoAurinia Pharmaceuticals Inc (AUPH) PT Set at $10.00 by Canaccord Genuity
www.americanbankingnews.com - March 12 at 10:51 PM
nasdaq.com logoAurinia (AUPH) Catches Eye: Stock Moves up 8.5% in Session - Nasdaq
www.nasdaq.com - March 10 at 9:31 PM
investopedia.com logoAurinia Offers Promising 2017 Forecast (AUPH)
www.investopedia.com - March 10 at 4:29 PM
zacks.com logoAurinia (AUPH) Catches Eye: Stock Moves up 8.5% in Session
www.zacks.com - March 10 at 8:12 AM
seekingalpha.com logoAurinia Pharmaceuticals: A Year In Review And A Bright Future Ahead
seekingalpha.com - March 9 at 9:21 PM
us.rd.yahoo.com logoAurinia Reports Fourth Quarter and Full Year 2016 Financial Results and Recent Operational Highlights
us.rd.yahoo.com - March 9 at 4:19 PM
americanbankingnews.com logoAurinia Pharmaceuticals Inc (AUPH) Given New $12.00 Price Target at HC Wainwright
www.americanbankingnews.com - March 9 at 9:00 AM
us.rd.yahoo.com logoToday's Research Reports on Trending Tickers: MeetMe and Aurinia Pharmaceuticals
us.rd.yahoo.com - March 8 at 4:23 PM
streetinsider.com logoAurinia Pharmaceuticals (AUPH) Ramps Higher Following Abstract Acceptance - StreetInsider.com
www.streetinsider.com - March 8 at 1:47 AM
fool.com logoHere's Why Aurinia Pharmaceuticals Stock Is Soaring Today
www.fool.com - March 7 at 3:43 PM
finance.yahoo.com logo4:06 pm Aurinia Pharma will present AURA-LV Phase IIb 48-week data of voclosporin for the treatment of lupus nephritis on April 20, 2017
finance.yahoo.com - March 7 at 9:06 AM
seekingalpha.com logoAurinia Pharmaceuticals (AUPH) Release AURA-LV 48-Week Topline Data - Slideshow
seekingalpha.com - March 3 at 8:58 PM
msn.com logoAurinia Pharmaceuticals (AUPH) Continues Momentum
www.msn.com - March 3 at 3:56 PM
us.rd.yahoo.com logoBiotech Industry Rally Grows as Trump Vows to Cut Regulations: Today's Reports on Aurinia Pharmaceuticals and Nektar Therapeutics
us.rd.yahoo.com - March 3 at 3:55 PM
seekingalpha.com logoAurinia Successful 48-Week Phase 2B Trial Results Even Better Than I Expected
seekingalpha.com - March 2 at 8:58 PM
rttnews.com logoAurinia Pharmaceuticals Inc. (AUPH) Is Challenging The Highs Of The Year
www.rttnews.com - March 2 at 8:58 PM
investopedia.com logoAurinia Pharma Spikes on Lupus Drug Safety (AUPH)
www.investopedia.com - March 2 at 8:58 PM
thestreet.com logoBiotech Premarket Movers: Aurinia, Puma, PTC, Juno
us.rd.yahoo.com - March 2 at 8:58 PM
us.rd.yahoo.com logoAurinia Pharma Spikes on Lupus Drug Safety
us.rd.yahoo.com - March 2 at 8:58 PM
us.rd.yahoo.com logoAurinia to Present at Cowen and Company 37th Annual Healthcare Conference
us.rd.yahoo.com - March 2 at 8:58 PM
rttnews.com logoAurinia Pharmaceuticals Inc. (AUPH) Is Climbing On Study Results
www.rttnews.com - March 1 at 8:41 PM
thestreet.com logoAurinia Pharma Kidney Drug Exits Study Update with Clean Safety Profile
us.rd.yahoo.com - March 1 at 8:41 PM
nasdaq.com logoAurinia Pharmaceuticals (AUPH) Shares March Higher, Can It Continue? - Nasdaq
www.nasdaq.com - February 23 at 1:45 AM
seekingalpha.com logoAurinia Pharmaceuticals: The World Awaits - Seeking Alpha
seekingalpha.com - February 16 at 3:48 PM
streetinsider.com logoAurinia Pharmaceuticals (AUPH) Announces Results From Phase I Ethnic Bridging Study for Voclosporin in Healthy Japanese Patients
www.streetinsider.com - February 16 at 8:37 AM
us.rd.yahoo.com logoAurinia Announces Results from Japanese Phase I Ethnic Bridging Study for Voclosporin
us.rd.yahoo.com - February 14 at 4:26 PM
streetinsider.com logoAurinia Pharmaceuticals (AUPH) Announces Results From Phase I Ethnic Bridging Study for Voclosporin in Healthy ... - StreetInsider.com
www.streetinsider.com - February 14 at 4:26 PM

Social

Frequently Asked Questions for Aurinia Pharmaceuticals (NASDAQ:AUPH)

What is Aurinia Pharmaceuticals' stock symbol?

Aurinia Pharmaceuticals trades on the NASDAQ under the ticker symbol "AUPH."

How were Aurinia Pharmaceuticals' earnings last quarter?

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) issued its earnings results on Tuesday, March, 31st. The company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of ($0.11) by $0.04. Aurinia Pharmaceuticals had a negative return on equity of 109.61% and a negative net margin of 9,512.50%.

Where is Aurinia Pharmaceuticals' stock going? Where will Aurinia Pharmaceuticals' stock price be in 2017?

6 equities research analysts have issued 1 year price objectives for Aurinia Pharmaceuticals' stock. Their forecasts range from $8.00 to $12.00. On average, they anticipate Aurinia Pharmaceuticals' stock price to reach $10.40 in the next twelve months.

What are analysts saying about Aurinia Pharmaceuticals stock?

Here are some recent quotes from research analysts about Aurinia Pharmaceuticals stock:

  • 1. FBR & Co analysts commented, "We increase our price target 22% from $9 to $11, as we think that with a balance sheet bolstered by a public offering that we estimate raised up to $161M in net proceeds, AUPH is now in a strong position to independently advance voclosporin (VCS), its investigational therapy for patients with active lupus nephritis (LN), into Phase III testing. As VCS is directed to an autoimmune disease that has been targeted by major pharmaceutical companies (Big Pharma) hungry for the next multi-billiondollar drug (FBR projects VCS could achieve >$2B in annual peak sales), we look for AUPH to receive an acquisition bid from a Big Pharma company in the next six to nine months, with an initial bid of $10 per share reasonable. We think AUPH is more likely to look to sign a partnership agreement; therefore, we look for a deal worth $500M to $700M in up-front and milestone payments to AUPH. We reiterate our Outperform rating." (3/22/2017)
  • 2. According to Zacks Investment Research, "Aurinia Pharmaceuticals Inc. is a late stage biopharmaceutical company. It focuses on the development of therapeutic immunomodulating drug candidate. The company's lead drug includes Voclosporin for the treatment of lupus nephritis. Aurinia Pharmaceuticals Inc. is headquartered in Victoria, Canada. " (3/20/2017)

Who owns Aurinia Pharmaceuticals stock?

Aurinia Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Acuta Capital Partners LLC (2.52%) and Oxford Asset Management (0.25%).

Who bought Aurinia Pharmaceuticals stock? Who is buying Aurinia Pharmaceuticals stock?

Aurinia Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including Acuta Capital Partners LLC and Oxford Asset Management.

How do I buy Aurinia Pharmaceuticals stock?

Shares of Aurinia Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Aurinia Pharmaceuticals stock cost?

One share of Aurinia Pharmaceuticals stock can currently be purchased for approximately $8.02.

Aurinia Pharmaceuticals (AUPH) Chart for Saturday, March, 25, 2017

This page was last updated on 3/25/2017 by MarketBeat.com Staff